RET

RET (REarranged during Transfection) is a receptor protein tyrosine kinase, which activates multiple signal transduction pathways. RET protein is composed of three domains: an extracellular ligand-binding domain, a transmembrane domain, and a cytoplasmic tyrosine kinase domain. The RET receptor tyrosine kinase (RTK) regulates key aspects of cellular proliferation and survival by regulating the activity of the mitogen- activated protein kinase (MAPK) and PI3K/Akt signaling pathways. RET also interacts directly with other kinases such as the epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (MET) and the focal adhesion kinase (FAK). Furthermore, BRAF and p38MAPK are downstream targets of RET. Kinase inhibitors that simultaneously inhibit RET and its downstream targets.

RET tyrosine kinase receptor presents an attractive therapeutic target for the treatment of certain cancer subsets. Deregulated RET activity has been identified as a causative factor in the development, progression and response to therapy of thyroid carcinoma. Elevated RET expression has been associated with the development of endocrine resistance in human breast cancer.

RET 相关产品(29)

  • GC67917 structure
    GC67917RET-IN-7
    CAS: 2763386-05-4

    RET-IN-7 在体外显示出强大的 RET 激酶抑制作用,在体内对 RET 驱动的肿瘤异种移植物具有强大的疗效。

  • GC68396 structure
    GC68396Vepafestinib
    CAS: 2129515-96-2
    纯度: >98.00%

    Vepafestinib (compound 6) 是 RET 的抑制剂 (信息来自专利 WO2019039439)。

  • GC68623 structure
    GC68623AD57
    CAS: 1093380-42-7
    纯度: >98.00%

    AD57 是一种具有口服活性的多种激酶抑制剂,抑制 RET、BRAF、S6K 和 Src 活性,但对 mTOR 的活性明显减弱。

  • GC68812 structure
    GC68812BT44
    CAS: 924759-42-2
    纯度: >99.00%

    BT44 是选择性 RET 活化剂。BT44 可穿透血脑屏障,可用于研究神经退行性疾病及糖尿病。

  • GC73196 structure
    GC73196RET-IN-21
    CAS: 2414373-42-3
    纯度: >97.00%

    RET-IN-21是受体酪氨酸激酶(RET)抑制剂,IC50为4.4 μM,具有抗肿瘤活性。